Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

Related Keywords

United States ,Houston ,Texas ,Brisbane ,Queensland ,Australia ,Jenene Thomas ,Walter Klemp ,Moleculin Biotech Inc ,Linkedin ,Company Investigational New Drug ,Emory University ,Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,Securities Exchange ,Facebook ,Prnewswire Moleculin Biotech Inc ,Investigational New Drug ,Transcription Modulator ,Regulatoryt Cells ,Diffuse Interstitial Pontine Glioma ,Orphan Drug Designation ,Rare Pediatric Disease ,Glioblastoma Multiforme ,Moleculin Biotech ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Although Moleculin ,